Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipperand sterile alpha motif-containing kinase (ZAK)

Details for Australian Patent Application No. 2010220262 (hide)

Owner Novartis AG

Inventors Fabbro, Doriano; Manley, Paul W.

Agent Davies Collison Cave

Pub. Number AU-A-2010220262

PCT Pub. Number WO2010/100248

Priority 09166437.5 27.07.09 EP; 09154507.9 06.03.09 EP

Filing date 5 March 2010

Wipo publication date 10 September 2010

International Classifications

A61K 31/166 (2006.01) - having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol

A61K 31/4406 (2006.01) - only substituted in position 3, e.g. zimeldine

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 13/00 (2006.01) Drugs for disorders of the urinary system

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

8 September 2011 PCT application entered the National Phase

  PCT publication WO2010/100248 Priority application(s): WO2010/100248

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010220263-3H-imidazo [4, 5 -C] pyridine6 - carboxamides as antiinflammatory agents

2010220260-Syringe, auto-injector device and set of auto-injector devices and syringes